

1	testimony as to damages after the parties submit additional briefing. During the Pretrial
2	Conference on December 3, 2020, the Court GRANTED in part and DENIED in part the Motion
3	for Determination of Issues before Trial (Dkt. No. 60). As set forth in full detail on the record,
4	the Court ruled as follows: (1) the issue of merchantability of the drugs remains undecided,
5	including as to Plaintiff's breach of the implied warranty of merchantability; (2) damages from
6	Plaintiff's loss of its license in Oman are not recoverable, and the scope of consequential
7	damages remains to be determined after the parties will submit briefing; and (3) evidence
8	concerning investigations by the FDA and Washington Department of Health shall be excluded,
9	but evidence as to Alfa Pharma's license status can be presented.
10	The clerk is ordered to provide copies of this order to all counsel.
11	Filed December 8, 2020.
12	William M. McCool
13	Clerk of Court
14	s/Paula McNabb Deputy Clerk
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	